FDA Issues Extensive Update About Revlimid, Second Cancers

The U.S. Food and Drug Administration issued an extensive update regarding the risk of developing a second cancer while being treated with Revlimid. The update comes on the heels of a change the FDA made to the prescribing information for Revlimid (lenalidomide) in March of this year.
The Myeloma Beacon